Parameter
| Biomarker | anti-PAD4 | Full name | Antipolyarginyldeimidease 4 antibody | Molecular Type | protein ( autoantibody ) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Supplementary diagnosis and treatment response prediction for seropositive type | ||
| Disease | Rheumatoid Arthritis (RA) | Disease Subtypes | / | ||
| Organ | Joint (Synovium) | Test Sample / Technology Platform | Serum (ELISA, electrochemical immunoassay platform) | ||
| Pathobiological Mechanisms | PAD4 catalyzes the conversion of arginine to citrulline, inducing autoantibody production and participating in the amplification of synovial inflammation; it is associated with disease severity and has predictive value for resistance to TNF inhibitors. | ||||
| Clinical Availability Status | Clinical trials in progress | ||||
| Notes and Dynamics | The electrochemical platform has a detection range of 10-500 IU/mL, superior to ELISA; approximately 60% of early RA patients are RF/anti-CCP negative but anti-PAD4 positive. | ||||